Treatment
S-1 clinical trials
We’re tracking 792 recruiting studies that include S-1, each written for real people, not researchers, below.
Recruiting studies
- NCT04512534RecruitingPhase 2
Check-in study of immunotherapy plus another drug for lymphoma
This Phase 2 trial tests whether combining sintilimab (an immunotherapy) with chidamide (an anticancer “epigenetic” drug) can shrink peripheral T-cell lymphoma that has come back or didn’t respond. It’s for adults who have measurable lymphoma spots and can safely take both medicines.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT01851694Recruiting
Study incretin hormone response in adults with cystic fibrosis
This study tests how the body’s “incretin” hormones affect insulin (sugar control) in adults with cystic fibrosis and certain blood sugar patterns. It may help explain what drives diabetes risk in cystic fibrosis and how the body responds to these hormone signals.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04431024Recruiting
Testing imaging and biopsy options for people with BAP1 risk
This study looks at how well advanced scans, liquid biopsy tests, and small follow-up procedures can find early mesothelioma in people with a high-risk BAP1 gene condition. It may help catch cancer earlier when treatment could work better.
Bethesda, MarylandAges 30–120 - NCT04388124RecruitingPhase 2
Test drug to block endothelin for hard-to-control blood pressure
This Phase 2 trial tests whether blocking endothelin (using bosentan and related treatments) can improve blood pressure in people with resistant hypertension—high blood pressure that stays high despite multiple medicines. It may help if your blood pressure is still above target even with the right combination of therapy.
RouenAges 18–80 - NCT04301076RecruitingPhase 1
Testing lenalidomide with EPOCH for adult T-cell leukemia-lymphoma
This trial tests whether adding lenalidomide to a standard chemotherapy regimen (EPOCH) helps people with adult T-cell leukemia-lymphoma (ATLL). It aims to improve how well the treatment works.
Atlanta, GeorgiaAges 18 years+ - NCT04347200Recruiting
Long-term blood-thinner therapy registry for heart disease
This study follows people with known coronary artery disease to understand how long-term “blood thinner” treatments are used and how they affect health over time. You may be asked to share medical information and come in for follow-up to help researchers compare outcomes.
MoscowAges 18 years+ - NCT04253964RecruitingPhase 2
Chemotherapy plus immunotherapy for advanced lung cancer
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
Charlotte, North CarolinaAges 18 years+ - NCT04239157RecruitingPhase 2
Canakinumab shot for lower-risk MDS and related blood disorders
This trial tests canakinumab, a medication that blocks inflammation, given as a skin (subcutaneous) injection. It is for adults with lower-risk myelodysplastic syndromes (MDS) or a related condition (chronic myelomonocytic leukemia or CCUS) to see if it can improve blood counts and reduce problems like anemia or transfusion needs.
Houston, TexasAges 18 years+ - NCT04174755Recruiting
Semaglutide for weight loss in adults with HIV
This trial studies whether semaglutide (a diabetes-type weight-loss injection) helps adults with HIV lose weight. It also checks that it’s safe for people whose HIV is well controlled on regular treatment.
Dublin, DublinAges 18 years+ - NCT04165772RecruitingPhase 2
Dostarlimab for locally advanced mismatch-repair deficient solid tumors
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
Hartford, ConnecticutAges 18 years+ - NCT04157127RecruitingPhase 1
Pancreatic cancer vaccine with chemotherapy before/around surgery
This early-stage trial tests a personalized immune “vaccine” made from dendritic cells, given alongside standard chemotherapy for pancreatic cancer that may be removable by surgery (resectable or borderline resectable). If it works, it may help your immune system better recognize and attack the cancer around the time of treatment.
Houston, TexasAges 18 years+ - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT03878706Recruiting
Testing diabetes medicines on heart risk and heart failure
This trial studies how diabetes medicines (GLP-1 and SGLT2, alone or together) affect the heart in people with type 2 diabetes who are at higher cardiovascular risk and have heart failure with preserved pumping function. It may help find safer or more effective ways to reduce heart problems.
Athens, AtticaAges 45–80 - NCT03938987RecruitingPhase 1/Phase 2
CAR T-cell therapy for CD19-positive aggressive lymphoma or ALL
This trial tests a lab-made immune therapy (CAR T-cells) that targets CD19, a marker found on certain lymphoma and leukemia cells. It’s for people whose lymphoma or ALL came back or did not respond to standard treatments, with the goal of getting the treatment to attack the cancer.
Calgary, AlbertaAges 2–70 - NCT03810339RecruitingPhase 2
Check a POLE/POLD cancer drug for non–MSI-high tumors
This Phase 2 trial studies toripalimab (JS001), given alone, in people whose tumors have specific POLE or POLD gene mutations but do not have MSI-H/dMMR. If it works, it may help shrink or control advanced solid tumors that have not responded to standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT03326921RecruitingPhase 1
T cell treatment for leukemia after a bone marrow transplant
This early-phase trial tests an immune “T cell” therapy made to recognize a specific leukemia target. It is for people whose acute leukemia has come back (relapsed) or did not fully respond after receiving a donor stem cell transplant.
Seattle, WashingtonAges Up to 80 years - NCT03259867RecruitingPhase 2
TACE plus immune therapy for liver or stomach cancer
This trial tests a combination treatment using a targeted liver procedure plus an immune “checkpoint” medicine to slow cancer growth. It may help people with advanced liver cancer (HCC) or metastatic stomach cancer when standard treatments have not worked.
Orange, CaliforniaAges 18–80 - NCT03031249Enrolling by invitationPhase 1/Phase 2
Testing ATO plus ATRA for NPM1-mutated AML after remission
This trial studies whether a combination medicine (ATO plus ATRA) is safe and works better in people with a specific type of AML (acute myeloid leukemia) caused by an NPM1 mutation. You would join only after your leukemia has reached remission, meaning the active leukemia has cleared after initial treatment.
Tianjin, Tianjin MunicipalityAges 14–55 - NCT02702869Enrolling by invitation
Study of improving care for common facial clefts
This trial is part of a quality-improvement and research program for people with typical facial clefts. It aims to help improve how care is organized and measured across treatment centers, which may benefit future patients and help your team deliver coordinated care.
Gainesville, FloridaAges 1 day–22 years - NCT00903110Recruiting
Long-term safety registry for Increlex in children
This study is a registry that follows children and teens with severe IGF-1 deficiency who use Increlex (or specific GH gene deletion situations) to better track long-term safety and effectiveness. You would likely join if your child is already starting or planning Increlex and is not in other growth-related drug trials.
Orange, CaliforniaAges 2–18 - NCT00884455Enrolling by invitation
Join the Alpha-1 DNA and tissue sample bank
This trial is a DNA and tissue sample registry for people interested in Alpha-1. It helps researchers study the condition by collecting samples for future research.
Gainesville, FloridaAges birth–100 years - NCT01212055Recruiting
Apheresis for certain immune system gene problems
This trial studies whether an apheresis procedure (removing blood cells through a machine) can help people with specific inherited immune system conditions. Participants will also receive filgrastim to help move certain blood-forming cells for collection.
Bethesda, MarylandAges 18–40 - NCT00767312Enrolling by invitation
Study how HIV multiplies during HIV drug treatment
This study looks at how HIV continues to multiply (or stays suppressed) while you are taking antiretroviral therapy, using blood samples. It may help researchers better understand what HIV is doing during treatment and why some people experience changes like viral rebound.
Bethesda, MarylandAges 18–99 - NCT00039689Recruiting
Blood collection study for newly diagnosed HIV research
This research study collects blood cells from people recently diagnosed with HIV who haven't started HIV medicines yet. Researchers use these samples to understand how HIV affects the immune system and develop better treatments.
Bethesda, MarylandAges 18–120
Common questions
- Are there clinical trials studying S-1?
- Yes. Clin2 currently lists 792 recruiting studies that include S-1, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a S-1 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is S-1 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether S-1 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.